Sign in
WithdrawnNo phase

Evaluating the Role of Pre-existing Resolvins in the Resolution of ICU Delirium

Key facts

Who runs it
Université Libre de Bruxelles
Where
Belgium1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
7 Oct 2023
Ended
30 Jun 2024
Type of study
Observational
Treatments tested
  • Study group
Record updated
30 March 2025
Why it stopped
COVID-19

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Non-ventilated, non-sedated adult patients with a planned ICU stay >72 hours. - - patients admitted due to an exacerbation of COPD
  • patients admitted due to severe trauma
  • patients admitted due to cardiogenic shock
  • patients admitted due to septic shock

Who cannot take part

  • Patients with known recreational drug and alcohol (ab)use
  • Patients with known neuro-psychiatric disorders
  • Patients who don't understand English, French or Dutch
  • Patients who are visually/auditory impaired (without glasses/ hearing aid)
  • Patients with a neurological trauma
  • Patients on ECMO

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

As patient management is improving, more and more ICU survivors are being confronted with cognitive dysfunction and this well after their hospital stay.

Read full original descriptionShow less

In the ICU, delirium rates have been reported to be as high at 81%. Delirium is associated with patient and family stress, increased hospital costs, increased duration of stay, escalation of care and increased mortality and morbidity.

The physiopathology of ICU cognitive impairment is complex and involves an inflammatory cascade Recently, the role of 'resolvins' derived from omega-3 fatty acids has been studied in the resolution of inflammation.

Therefore, this hypothesis of this study is that ICU patients with higher serum levels of resolvins at ICU admission, ICU day 2 and day 5 will have a lesser degree of cognitive impairment on day 5 of ICU stay.

Treatments tested

  • Study group

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
30 March 2025